WARRANTS

12 Months Ended

Mar. 31, 2022

WARRANTS

NOTE 8 - WARRANTS

NOTE 8 – WARRANTS

During the year ended March 31, 2021, the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years from grant date and are convertible into common stock at $0.15 per share. The warrants contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price.

The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021 the valuation resulted in a deemed dividend from the down round calculation of $555,000 with a recalculated conversion price change to $0.04 per share.

The weighted average remaining life and intrinsic value of the warrants as of March 31, 2022 was.

	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contract Life		Intrinsic Value
Outstanding at March 31, 2020		--	$	0.00	0.00	$	-
Granted		3,700,000		0.15	2.00
Exercised		--		-	--		--
Expired		--		-	--		--
Outstanding at March 31, 2021		3,700,000	$	0.04	1.35	$	-
Granted		--
Exercised		--
Expired		--
Outstanding at March 31, 2022		3,700,000	$	0.04	0.35	$	-

As of March 31, 2022 there were 3,700,000 warrants outstanding.